Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.52 --0%
Revenue Growth %: +91.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +91.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted by Citi on continued demand strength
- SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
- Darden Restaurants (DRI) Tops Q4 EPS by 3c, Misses on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
